Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

UK vaccine chief targets spring rollout, but impact may be limited

Published 28/10/2020, 00:32
Updated 28/10/2020, 13:50
© Reuters. FILE PHOTO: Small bottles labeled with "Vaccine" stickers stand near a medical syringe in front of displayed "Coronavirus COVID-19" words in this illustration

By Alistair Smout and Kanishka Singh

(Reuters) - The woman in charge of procuring possible COVID-19 vaccines for Britain said that rollout of the earliest shots could start this year, though their effectiveness was likely to be limited.

There is no clinically proven vaccine against the coronavirus, though nearly 200 candidates are in development worldwide, and late-stage trial results are expected for the first of them by the end of 2020.

Britain has agreed supply deals for six candidates including frontrunners from AstraZeneca and Pfizer (NYSE:PFE).

"If the first two vaccines, or either of them, show that they are both safe and effective, I think there is a possibility that vaccine rollout will start this side of Christmas," Kate Bingham said on BBC television.

"... Otherwise I think it's more realistic to expect it to be early next year."

Bingham, the chair of the UK Vaccine Taskforce, had written in an opinion piece published overnight that all the candidate vaccines could in theory fail.

"We do not know that we will ever have a vaccine at all", she wrote in the Lancet medical journal https://

"The first generation of vaccines is likely to be imperfect, and we should be prepared that they might not prevent infection but rather reduce symptoms and, even then, might not work for everyone or for long."

One independent experts agreed that over-reliance on vaccines was unwise.

"It's unlikely that we'll find a perfect vaccination that will protect everybody 100%," said Chris Butler, a primary care professor at Oxford University. "(Some) people will still be getting this acute illness, (so) finding treatments ... will continue to be important."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Environment Minister George Eustice told Sky News on Wednesday that a vaccine would be the answer to the COVID-19 crisis, but that Bingham's Lancet analysis was "probably right."

Bingham also cautioned that the global manufacturing capacity for vaccines was vastly inadequate for the billions of doses that were needed, and that Britain's manufacturing capability to date had been "equally scarce".

With over 900,000 infections and more than 45,000 deaths, Britain's COVID-19 epidemic has been one of the world's deadliest, and on Tuesday daily fatalities hit their highest level since May.

Prime Minister Boris Johnson is using a strategy of local lockdowns to try and contain its second wave, which reports in the Telegraph newspaper said the government was expecting to be more deadly than the first.

Latest comments

Buy from Russia and get people vaccinate. Russia get vaccines from Ebola first, Covid first and less talking, they are doing...
Better buy that good tea from Russia.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.